Targeting cell-cycle machinery in cancer.


Journal

Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617

Informations de publication

Date de publication:
14 06 2021
Historique:
received: 24 11 2020
revised: 09 02 2021
accepted: 26 03 2021
pubmed: 24 4 2021
medline: 18 12 2021
entrez: 23 4 2021
Statut: ppublish

Résumé

Abnormal activity of the core cell-cycle machinery is seen in essentially all tumor types and represents a driving force of tumorigenesis. Recent studies revealed that cell-cycle proteins regulate a wide range of cellular functions, in addition to promoting cell division. With the clinical success of CDK4/6 inhibitors, it is becoming increasingly clear that targeting individual cell-cycle components may represent an effective anti-cancer strategy. Here, we discuss the potential of inhibiting different cell-cycle proteins for cancer therapy.

Identifiants

pubmed: 33891890
pii: S1535-6108(21)00168-9
doi: 10.1016/j.ccell.2021.03.010
pmc: PMC8206013
mid: NIHMS1695086
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Cyclin D 0
Cyclin E 0
CDK4 protein, human EC 2.7.11.22
CDK6 protein, human EC 2.7.11.22
Cyclin-Dependent Kinase 4 EC 2.7.11.22
Cyclin-Dependent Kinase 6 EC 2.7.11.22

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

759-778

Subventions

Organisme : NCI NIH HHS
ID : P50 CA168504
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA202634
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA236226
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA247375
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests P.S. has been a consultant at Novartis, Genovis, Guidepoint, The Planning Shop, ORIC Pharmaceuticals, Cedilla Therapeutics, Syros Pharmaceuticals and Exo Therapeutics; his laboratory received research funding from Novartis.

Références

Cancer Cell. 2018 Jul 9;34(1):9-20
pubmed: 29731395
BMC Cancer. 2014 Jan 20;14:32
pubmed: 24444383
Cancer Res. 2018 Oct 1;78(19):5481-5491
pubmed: 30194068
Science. 2004 Oct 29;306(5697):885-8
pubmed: 15514162
Mol Cell Biol. 1997 Jan;17(1):453-9
pubmed: 8972226
Cancer Cell. 2010 Jul 13;18(1):63-73
pubmed: 20609353
Cancer Res. 1996 Sep 15;56(18):4159-63
pubmed: 8797586
Semin Cell Dev Biol. 2020 Nov;107:28-35
pubmed: 32334991
Angew Chem Int Ed Engl. 2020 Aug 10;59(33):13865-13870
pubmed: 32415712
Mol Cell. 2019 Jan 3;73(1):22-35.e6
pubmed: 30527665
Clin Breast Cancer. 2014 Jun;14(3):169-76
pubmed: 24393852
J Cell Biol. 2012 Jan 9;196(1):147-62
pubmed: 22232705
Curr Biol. 2003 Oct 14;13(20):1775-85
pubmed: 14561402
Nat Rev Cancer. 2009 Mar;9(3):153-66
pubmed: 19238148
Nat Commun. 2017 Aug 30;8(1):386
pubmed: 28855512
Clin Cancer Res. 2019 Jan 1;25(1):6-8
pubmed: 30115629
Cancer Cell. 2012 Oct 16;22(4):438-51
pubmed: 23079655
Nature. 1995 Jul 6;376(6535):88-91
pubmed: 7596441
Br J Cancer. 1999 Aug;80(12):2001-7
pubmed: 10471053
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3761-6
pubmed: 21321214
Nat Chem Biol. 2008 Jun;4(6):357-65
pubmed: 18469809
Mol Cell Biol. 2001 Sep;21(18):6254-69
pubmed: 11509668
Mol Cell. 2007 Jan 12;25(1):127-39
pubmed: 17218276
Blood. 2020 Apr 30;135(18):1560-1573
pubmed: 32040545
Science. 2018 Dec 21;362(6421):1416-1422
pubmed: 30573629
Transl Oncol. 2016 Dec;9(6):548-556
pubmed: 27863310
Cancers (Basel). 2020 May 30;12(6):
pubmed: 32486290
Clin Cancer Res. 2010 Sep 15;16(18):4503-8
pubmed: 20647475
Cancer Cell. 2014 Dec 8;26(6):909-922
pubmed: 25490451
Lancet Oncol. 2021 Feb;22(2):212-222
pubmed: 33460574
Lung Cancer. 2014 Feb;83(2):219-23
pubmed: 24388167
Blood. 2012 May 17;119(20):4597-607
pubmed: 22383795
Clin Cancer Res. 2020 Jan 1;26(1):110-121
pubmed: 31527167
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14010-5
pubmed: 19666607
Oncogene. 1998 Jun 4;16(22):2865-78
pubmed: 9671407
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
Nat Rev Drug Discov. 2017 Feb;16(2):101-114
pubmed: 27885283
Elife. 2019 Dec 31;8:
pubmed: 31889509
Breast Cancer Res. 2009;11(5):R77
pubmed: 19874578
Cancer Res. 2002 Nov 15;62(22):6414-7
pubmed: 12438226
Clin Cancer Res. 2013 Nov 1;19(21):5960-71
pubmed: 24004674
Lancet Oncol. 2020 Feb;21(2):250-260
pubmed: 31859246
Sci Adv. 2020 Jun 17;6(25):eabb2210
pubmed: 32704543
J Transl Med. 2013 Oct 16;11:259
pubmed: 24131779
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1015-1020
pubmed: 29339491
Cell. 2018 Nov 1;175(4):984-997.e24
pubmed: 30388455
Invest New Drugs. 2015 Aug;33(4):890-4
pubmed: 25947565
PLoS One. 2015 May 11;10(5):e0126875
pubmed: 25962181
Nat Struct Mol Biol. 2020 Jul;27(7):605-614
pubmed: 32541897
Cancer Discov. 2020 Aug;10(8):1174-1193
pubmed: 32404308
Oncotarget. 2015 Aug 28;6(25):20801-12
pubmed: 26204491
Cancer Cell. 2013 Aug 12;24(2):167-81
pubmed: 23948297
Cell. 2006 Jan 13;124(1):89-103
pubmed: 16413484
Cancer Res. 2014 Jul 15;74(14):3870-9
pubmed: 24802190
Nat Rev Drug Discov. 2015 Feb;14(2):130-46
pubmed: 25633797
Cell Mol Life Sci. 2014 Dec;71(24):4881-94
pubmed: 24879294
Nat Genet. 2003 Sep;35(1):25-31
pubmed: 12923533
Oncogene. 2005 Apr 18;24(17):2776-86
pubmed: 15838514
Lancet Oncol. 2015 Jan;16(1):25-35
pubmed: 25524798
Tumour Biol. 2014 Jun;35(6):5395-9
pubmed: 24519066
J Biol Chem. 2001 Aug 10;276(32):29702-10
pubmed: 11359766
Cancer Res. 2011 May 1;71(9):3377-86
pubmed: 21385896
Breast Cancer Res. 2019 Jul 1;21(1):77
pubmed: 31262335
Lancet Oncol. 2019 Nov;20(11):1587-1601
pubmed: 31575503
Bioorg Med Chem Lett. 2019 Jun 1;29(11):1375-1379
pubmed: 30935795
Nature. 2014 Apr 24;508(7497):541-5
pubmed: 24670654
Clin Cancer Res. 2020 Feb 15;26(4):922-934
pubmed: 31699827
Oncotarget. 2017 Aug 4;8(47):81754-81775
pubmed: 29137220
J Clin Oncol. 2019 May 10;37(14):1169-1178
pubmed: 30807234
Cell. 2014 Nov 20;159(5):1126-1139
pubmed: 25416950
DNA Repair (Amst). 2018 Dec;72:99-106
pubmed: 30266203
Cell Rep. 2016 Feb 9;14(5):979-990
pubmed: 26804906
Cancer Res. 2006 Jan 1;66(1):6-9
pubmed: 16397206
Am J Pathol. 2010 Oct;177(4):2034-45
pubmed: 20724597
Cancer Metastasis Rev. 2020 Sep;39(3):805-823
pubmed: 32385714
Oncogene. 2018 May;37(21):2850-2862
pubmed: 29511348
Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):9282-9287
pubmed: 30150405
Sci Adv. 2019 May 22;5(5):eaav3660
pubmed: 31131319
Nat Cell Biol. 2010 Jan;12(1):54-9; sup pp 1-14
pubmed: 20010815
Clin Cancer Res. 2009 Feb 15;15(4):1417-27
pubmed: 19193619
Science. 2016 Sep 30;353(6307):1549-1552
pubmed: 27708105
Nat Rev Cancer. 2001 Dec;1(3):222-31
pubmed: 11902577
Genes Dev. 1999 Sep 15;13(18):2375-87
pubmed: 10500095
Cancer Cell. 2003 Dec;4(6):451-61
pubmed: 14706337
Nat Rev Cancer. 2017 Jan 27;17(2):93-115
pubmed: 28127048
Cell. 2015 Sep 24;163(1):174-86
pubmed: 26406377
Oncol Lett. 2019 May;17(5):4455-4462
pubmed: 30988814
Adv Exp Med Biol. 2017;1042:527-547
pubmed: 29357072
J Biol Chem. 2005 Apr 15;280(15):15148-57
pubmed: 15708847
Cell Cycle. 2013 Feb 15;12(4):606-17
pubmed: 23324395
Cell Chem Biol. 2019 Jun 20;26(6):792-803.e10
pubmed: 30905681
Cancer Sci. 2007 May;98(5):644-51
pubmed: 17359284
Expert Rev Mol Diagn. 2003 Sep;3(5):617-33
pubmed: 14510182
Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326
pubmed: 30802347
Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3826-31
pubmed: 22355113
Cell Mol Life Sci. 2002 Aug;59(8):1317-26
pubmed: 12363035
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):E1019-27
pubmed: 22474407
Br J Cancer. 2010 Jan 19;102(2):342-50
pubmed: 20010939
Cancer Cell. 2017 Dec 11;32(6):761-776.e6
pubmed: 29232554
J Exp Med. 2012 Apr 9;209(4):679-96
pubmed: 22430491
Nat Med. 2007 Jul;13(7):820-7
pubmed: 17589519
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12968-73
pubmed: 19525400
Front Oncol. 2018 Aug 08;8:303
pubmed: 30135856
Drug Des Devel Ther. 2009 Feb 06;2:255-64
pubmed: 19920912
Neoplasia. 2008 Sep;10(9):920-31
pubmed: 18714392
Clin Cancer Res. 2020 Feb 1;26(3):566-580
pubmed: 31615937
Nature. 2017 Jun 15;546(7658):426-430
pubmed: 28607489
Cancer Discov. 2018 Feb;8(2):216-233
pubmed: 29101163
Curr Cancer Drug Targets. 2015;15(3):196-204
pubmed: 25643258
Cancer Cell. 2020 Jan 13;37(1):37-54.e9
pubmed: 31883968
Oncogene. 2003 Mar 20;22(11):1724-9
pubmed: 12642875
Br J Cancer. 2016 Sep 6;115(6):682-90
pubmed: 27529512
Cell Cycle. 2007 Dec 1;6(23):2982-9
pubmed: 18156799
Cell Cycle. 2020 Oct;19(20):2589-2599
pubmed: 32975478
Mol Cancer Ther. 2018 Jun;17(6):1156-1166
pubmed: 29545334
J Biol Chem. 2013 Aug 23;288(34):24494-502
pubmed: 23853094
J Clin Invest. 2018 Feb 1;128(2):644-654
pubmed: 29337311
Nat Cell Biol. 2014 Jun;16(6):538-49
pubmed: 24776885
PLoS One. 2010 Nov 12;5(11):e15498
pubmed: 21103391
J Clin Oncol. 2006 Apr 10;24(11):1770-83
pubmed: 16603719
Cancer Res. 2009 Apr 1;69(7):2817-25
pubmed: 19318554
Nature. 2017 Aug 24;548(7668):471-475
pubmed: 28813415
Cancer Res. 2016 Apr 15;76(8):2301-13
pubmed: 27020857
Mol Cancer Ther. 2010 Aug;9(8):2344-53
pubmed: 20663931
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):58-63
pubmed: 19966300
Mol Cancer Ther. 2004 Nov;3(11):1427-38
pubmed: 15542782
Nat Commun. 2018 Dec 7;9(1):5235
pubmed: 30531861
Cancer Res. 2011 Oct 1;71(19):6174-83
pubmed: 21844184
Cell Rep. 2018 Mar 13;22(11):2978-2994
pubmed: 29539425
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Oncogene. 1999 Dec 16;18(54):7816-24
pubmed: 10618723
Nature. 2014 Jul 31;511(7511):616-20
pubmed: 25043025
Nat Rev Clin Oncol. 2016 Jul;13(7):417-30
pubmed: 27030077
Cancer Res. 2016 Apr 15;76(8):2406-18
pubmed: 26928812
Sci Adv. 2020 Apr 17;6(16):eaaz9899
pubmed: 32494624
Cell. 2009 Jul 23;138(2):352-65
pubmed: 19592082
Cell Chem Biol. 2019 Feb 21;26(2):300-306.e9
pubmed: 30595531
Cancer Cell. 2020 Apr 13;37(4):514-529
pubmed: 32289274
Nature. 2019 Oct;574(7777):268-272
pubmed: 31578521
EMBO Mol Med. 2017 Aug;9(8):1052-1066
pubmed: 28566333
Oncol Lett. 2019 Nov;18(5):4651-4658
pubmed: 31611974
Blood. 2017 Mar 30;129(13):1876-1878
pubmed: 28126927
Clin Cancer Res. 2017 Apr 1;23(7):1862-1874
pubmed: 27663592
Cancer Res. 2009 Aug 1;69(15):6208-15
pubmed: 19638587
Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727-31
pubmed: 22560567
J Steroid Biochem Mol Biol. 2014 Oct;144 Pt B:471-82
pubmed: 25220500
Mol Cancer Ther. 2011 Sep;10(9):1624-34
pubmed: 21768328
Cancer Cell. 2003 Mar;3(3):233-45
pubmed: 12676582
Cell Death Differ. 2021 Feb;28(2):427-438
pubmed: 33130827
Mol Cancer Ther. 2016 Apr;15(4):593-607
pubmed: 26826118
Genes Dev. 2004 Nov 15;18(22):2699-711
pubmed: 15545627
Cancer Cell. 2020 Mar 16;37(3):340-353.e6
pubmed: 32109375
Mol Syst Biol. 2018 Mar 5;14(3):e7858
pubmed: 29507054
PLoS One. 2013;8(3):e59588
pubmed: 23527225
Nature. 2007 Aug 16;448(7155):811-5
pubmed: 17700700
Oncogene. 2019 May;38(20):3886-3902
pubmed: 30692638
J Clin Oncol. 2020 Dec 1;38(34):3987-3998
pubmed: 32954927
Cell Cycle. 2007 Jun 15;6(12):1437-42
pubmed: 17581275
Oncotarget. 2017 Aug 10;8(48):83925-83939
pubmed: 29137393
Oncotarget. 2017 Jun 27;8(26):42343-42358
pubmed: 28418845
Stem Cell Reports. 2015 Mar 10;4(3):374-89
pubmed: 25733019
Mol Immunol. 2002 May;38(12-13):981-7
pubmed: 12009577
Nature. 2018 Jan 4;553(7686):91-95
pubmed: 29160310
Mol Cancer Ther. 2016 Oct;15(10):2273-2281
pubmed: 27496135
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882
Mol Cancer Ther. 2012 Jul;11(7):1488-99
pubmed: 22564725
Cancer Res. 2004 Oct 1;64(19):7110-6
pubmed: 15466207

Auteurs

Jan M Suski (JM)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.

Marcin Braun (M)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Department of Pathology, Chair of Oncology, Medical University of Lodz, 92-213 Lodz, Poland.

Vladislav Strmiska (V)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.

Piotr Sicinski (P)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA. Electronic address: peter_sicinski@dfci.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH